<DOC>
	<DOCNO>NCT01614366</DOCNO>
	<brief_summary>The purpose study compare different dose DMTA07 ( DM ) combine amlodipine treatment mild moderate essential hypertension , define optimize dose DM combination therapy .</brief_summary>
	<brief_title>DMTA07 Combine With Amlodipine Treatment Patients With Hypertension</brief_title>
	<detailed_description>To compare different dose DM combine amlodipine treatment mild moderate essential hypertension , define optimize dose DM combination therapy . The purpose study compare antihypertensive efficacy tolerability different dose DM combine amlodipine treatment , explore optimized combination dose DM .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Male female patient age 50 75 year old ( include ) ; 2 . Patient mild moderate essential hypertension enrollment , define follow : Patient must mean sit SBP ≥140 &lt; 180 mmHg mean sit DBP ≥90 &lt; 110 mmHg enrollment ; 3 . Patient normal serum potassium ; 4 . Patient his/her legally acceptance representative sign write informed consent form . 1 . Patient severe hypertension ( mean sit DBP ≥ 110 mmHg mean sit SBP ≥ 180 mmHg ) ; 2 . Patient secondary hypertension , coarctation aorta , hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing 's disease , pheochromocytoma , polycystic kidney disease , etc ; 3 . Patient treatment betablocker prior enrollment ; 4 . A definite diagnosis unstable cardiovascular disease , include angina pectoris , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , transient ischemic attack , stroke , arrhythmia heart failure within 3 month sign write informed consent form ; 5 . Patient concomitant endocrine disease type 1 Diabetes Mellitus ; 6 . Patient type 2 Diabetes Mellitus poor glucose control ( glycosylated hemoglobin &gt; 9 % fast blood sugar &gt; 250 mg/dL enrollment ) insulin treatment ; 7 . Patient clinically unstable disease know collagen autoimmune disease malignant disease require current medication ; 8 . Patient bilateral renal artery stenosis , solitary kidney post renal transplant ; 9 . Patient clinically relevant hematological disease ; 10 . Hepatic renal dysfunction define follow parameter : ALT AST &gt; 2 time upper limit normal , Total bilirubin &gt; 2 time upper limit normal , Serum creatinine &gt; 2.0 mg/dl ; 11 . Female patient pregnant lactating ; 12 . Patient substance abuse ( include alcohol ) history past two year ; 13 . Known suspected contraindication , include allergy DMTA07 calcium channel blocker ; 14 . Patient receive investigational drug device within 30 day sign write informed consent form ; 15 . Patient serious disease consider investigator ( ) condition enter trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>amlodipine</keyword>
	<keyword>DMTA07</keyword>
	<keyword>hypertension</keyword>
</DOC>